Condition
Recurrent NSCLC
Total Trials
6
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
Termination Rate
33.3%
2 terminated out of 6 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
5Total
P 1 (2)
P 2 (2)
P 4 (1)
Trial Status
Terminated2
Unknown2
Active Not Recruiting1
Recruiting1
Clinical Trials (6)
Showing 6 of 6 trials
NCT05786924Phase 1Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05891197Terminated
A Biomarker Screening Protocol for Participants With Solid Tumors
NCT05274451Phase 1Terminated
A Study to Investigate LYL797 in Adults With Solid Tumors
NCT04027647Phase 2Active Not Recruiting
Phase 2 Study of Dacomitinib in NSCLC
NCT04846452Phase 2Unknown
Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC
NCT00813332Phase 4Unknown
Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)
Showing all 6 trials